Claims
- 1. A naphthalene derivative represented by the following general formula or a pharmacologically acceptable salt thereof: ##STR144## wherein R.sup.1 stands for a hydrogen atom or a lower alkyl, acyl or arylalkyl group;
- R.sup.2 stands for a hydrogen atom or a lower alkyl, lower alkoxy, cycloalkoxy or acyl group;
- R.sup.3 stands for: the formula: ##STR145## wherein R.sup.10 and R.sup.11 may be the same or different from each other and each stands for a hydrogen atom, a hydroxyl, lower alkyl, lower alkoxy, aryl, heteroaryl group or a group represented by the formula: --(CH.sub.2).sub.q --COOH (wherein q is an integer of 1 to 2), or alternatively R.sup.10 and R.sup.11 may form a ring which may contain a nitrogen, oxygen or sulfur atom together with the nitrogen atom to which R.sup.10 and R.sup.11 are bonded);
- Z stands for a group represented by the formula: ##STR146## (wherein R.sup.5 and R.sup.6 may be the same or different from each other and each stands for a hydrogen atom or a lower alkyl, alkenylalkyl, alkynylalkyl or aryl group, an arylalkyl group, the aryl group of which may be substituted, a halogen atom or a heteroarylalkyl, cycloalkyl, cycloalkylalkyl, lower alkoxyalkyl, heterocycloalkyl or cyano group, or alternatively R.sup.5 and R.sup.6 may form a ring together with the carbon atom to which R.sup.5 and R.sup.6 are bonded), a group represented by the formula: .dbd.N--OR.sup.7 (wherein R.sup.7 stands for a lower alkyl group) or an oxygen atom;
- Y stands for a group represented by the formula: --(CH.sub.2).sub.n -- (wherein n is 0 or an integer of 1 to 2) or a group represented by the formula: ##STR147## (wherein R.sup.8 and R.sup.9 may be the same or different from each other and each stands for a lower alkyl group); and
- R.sup.4 stands for a hydrogen atom, a lower alkyl group or a group represented by the formula: ##STR148## (wherein p is 0 or an integer of 1 to 3 and R.sup.12 stands for a hydrogen or halogen atom or a lower alkyl or lower alkoxy group).
- 2. A naphthalene derivative or a pharmacologically acceptable salt thereof as claimed in claim 1, wherein R.sup.4 is a benzyl group.
- 3. A naphtahlene derivative or a pharmacologically acceptable salt thereof as claimed in claim 1, wherein R.sup.1 is a hydrogen atom or a lower alkyl group.
- 4. A naphtahlene derivative or a pharmacologically acceptable salt thereof as claimed in claim 3, wherein the lower alkyl group is a methyl group.
- 5. A naphtahlene derivative or a pharmacologically acceptable salt thereof as claimed in claim 1, wherein R.sup.2 is a lower alkoxy group.
- 6. A naphtahlene derivative or a pharmacologically acceptable salt thereof as claimed in claim 5, wherein the lower alkoxy group is a methoxy group.
- 7. A naphtahlene derivative or a pharmacologically acceptable salt thereof as claimed in claim 1, wherein R.sup.3 is a hydroxy group.
- 8. A naphtahlene derivative or a pharmacologically acceptable salt thereof as claimed in claim 1, wherein Y is a group represented by the formula: --(CH.sub.2).sub.n -- (wherein n is 0).
- 9. A naphtahlene derivative or a pharmacologically acceptable salt thereof as claimed in claim 1, wherein Z is a group represented by the formula: ##STR149## (wherein R.sup.5 and R.sup.6 may be the same or different from each other and each stands for a hydrogen atom, a lower alkyl group, an alkenylalkyl group, an arylalkyl group whose aryl group may be substituted or a halogen atom).
- 10. A naphtahlene derivative or a pharmacologically acceptable salt thereof as claimed in claim 1, wherein R.sup.1 is a hydrogen atom, R.sup.2 is a methoxy group, R.sup.3 is a hydroxyl group, Y is a group represented by the formula: --(CH.sub.2).sub.n -- (wherein n is 0), Z is a group represented by the formula: ##STR150## (wherein R.sup.5 and R.sup.6 may be the same or different from each other and each stands for a hydrogen atom, a lower alkyl group, an alkenylalkyl group, an arylalkyl group whose aryl group may be substituted or a halogen atom), and R.sup.4 is a benzyl group.
- 11. A pharmaceutical composition which comprises a therapeutically effective amount of the naphthalene derivative or the pharmacologically acceptable salt thereof defined in claim 1 and a pharmacologically acceptable carrier.
- 12. A method for treatment of a disease which comprises administering a pharmaceutically effective amount of the naphthalene derivative or the pharmacologically acceptable salt thereof defined in claim 1 to a patient suffering from a disease which the production of prostaglandin is rised.
- 13. A method for treatment of a disease which comprises administering a pharmaceutically effective amount of the naphthalene derivative or the pharmacologically acceptable salt thereof defined in claim 1 to a patient suffering from a disease which the production of leukotrienes is rised.
- 14. A method for treatment of a disease which comprises administering a pharmaceutically effective amount of the naphthalene derivative or the pharmacologically acceptable salt thereof defined in claim 1 to a patient suffering from an inflammatory disease.
- 15. A method for treatment of a disease which comprises administering a pharmaceutically effective amount of the naphthalene derivative or the pharmacologically acceptable salt thereof defined in claim 1 to a patient suffering from a disease selected from the group consisting of chronic rheumatoid arthritis, osteoarthritis, shoulder periarthritis, cervicobrachial syndrome and lumbago.
Priority Claims (1)
Number |
Date |
Country |
Kind |
2-311066 |
Nov 1990 |
JPX |
|
Parent Case Info
This is a division of application Ser. No. 07/790,541, filed Nov. 12, 1991, now U.S. Pat. No. 5,262,565.
Non-Patent Literature Citations (3)
Entry |
CA 113(5):40087 1990. |
CA 112(19):178286 1990. |
CA 75(25):151608 1971. |
Divisions (1)
|
Number |
Date |
Country |
Parent |
790541 |
Nov 1991 |
|